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Throughout the manuscript, the authors state that they identified "incident diagnosis of CKD, HF, or diabetes". After reading the paper I take this to mean the first record within the data, rather than the first ever event for that individual. Is this correct? I think some clarification or clearer language around this definition is required.
This also has implications for the quality of the matching procedure, which includes variables such as time from CKD diagnosis or diabetes duration. Is this measured only within the time frame of the data, or does it relate to historical clinical data?
The methods for the matching should be stated more clearly. For instance, was 1:1 matching used? I think so, but some numbers in table 2 differ by cases and controls. And how was matching performed, i.e. exact match, propensity scores, etc.?
The subgroup analyses by HK severity are based on non-mutually exclusive groups, e.g. all patients in the >6 mmol/L analysis also contribute to the >5 mmol/L. Would it not be preferable to split patients into mutually exclusive groups?
Possibly a major limitation of the analyses, is the absence of any confidence intervals around the estimates of costs.
I think there is insufficient discussion of the rationale for this research, and descriptions of how the results might be used. Their use has implications for the interpretability of the results, as discussed below.
As the authors themselves note, it is not clear whether these results are driven by the HK itself, or whether the HK is indicative of other underlying conditions. How important this is, depends on how this data might be used, and provides further need for greater description of the rationale of this research.
Also, would it not be possible with the data the authors have to explore to what extent these results are driven by other conditions, e.g. what events are individuals hospitalised for with elevated HK?
The 'Conclusions' in the abstract should provide some indication of the value of this research. Currently it restates some of the results.
The main cost results are excess costs over 6 months. This needs to be made clearer throughout the manuscript whenever results are presented.
From Table 2 , there is some evidence of residual confounding after matching -i.e. some differences in characteristic profiles. What impact do the authors think this has on the results?
In the comparison with previous literature, the authors state that costs in their study were comparable to a previous US study (Fitch et al). It's not clear to me this is the case. While the authors of this study estimated a difference in 6-month costs of HK for CKD patients of $5,600, the corresponding estimate from Fitch would be about $18,000. Perhaps I have misinterpreted this? It is not necessarily a problem that estimates differ from a US study because, as the authors note, there are major differences between the two healthcare systems.
The Conclusions section of the paper is perhaps too strong given the limitations identified at the end of the Discussion.
Figure 4 presents costs and cost differences for each disease group. The bars showing the difference (when positive) should not be hovering up the scale. I realise they are showing the difference, but it may be misleading as they no longer conform to the y-axis values. They should start at 0 and end at the mean cost as standard.
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GENERAL COMMENTS
Overall it is nice to see an attempt to publish this data. There is limited information regarding hyperkalemic events in Europe, so the publication of this registry would be a welcomed additional to the available evidence. However there are some issues that need to be resolved prior to publication. 
Please leave your comments for the authors below
The data used in this analysis is of extremely high-quality, and the study seems largely wellconducted. I have a few comments about the description of the methods and interpretation of the results, and some methodological questions.
RESPONSE: We thank Dr. Kent for the kind comments on the quality of our Danish data, and we are very grateful for the pertinent comments and suggestions that have helped us improve the quality of our manuscript.
Throughout the manuscript, the authors state that they identified "incident diagnosis of CKD, HF, or diabetes". After reading the paper I take this to mean the first record within the data, rather than the first ever event for that individual. Is this correct? I think some clarification or clearer language around this definition is required. This also has implications for the quality of the matching procedure, which includes variables such as time from CKD diagnosis or diabetes duration. Is this measured only within the time frame of the data, or does it relate to historical clinical data?
RESPONSE: It is correct that with incident diagnosis, we mean the first incident record of CKD, HF, or diabetes in our registries, i.e. first record of CKD either through laboratory tests or hospital codes; first record of HF through a hospital inpatient admission diagnosis, and first record of drug-treatment for diabetes. We have clarified these definitions in the revised manuscript. We thus defined incident records of CKD, HF, or diabetes, respectively, between 1 January 2005 and 30 June 2011, and then made sure that persons had no previous record of the respective disease in question before 1 January 2005. Our available look-back period was back to 1977 for hospital codes, to 1998 for prescription data, and to 2000 for laboratory data.
The same applies to matching on disease duration, i.e. time since first incident record in the medical registries was used for both hyperkalemia and non-hyperkalemia individuals, with several years of look-back before beginning of the study period. We have now clarified this in the revised manuscript.
The methods for the matching should be stated more clearly. For instance, was 1:1 matching used? I think so, but some numbers in figure (Figure 1 ) in the revised manuscript. We ranked the matching criteria based on what we thought would be the most clinically important factors. First we tried to find a match with the same values for all matching factors (and picked a random if more than one match were identified). If we couldn't find that, we tried to find a patient with the same values for all but the least important factor on the list. We continued this until we found a match for virtually all patients, using all possible combinations of variables in ranked order.
RESPONSE: In our analyses, we were not intending to compare mutually exclusive groups. The explicit aim of our analyses by HK severity was to explore cost differences when applying different definitions of HK, as these definitions vary in the literature, between countries and are used in guidelines and treatment decisions. Therefore, we applied commonly used potassium cut-off levels such as ">5.0 mmol/L", ">5.5 mmol/L", and ">6.0 mmol/L". We have clarified this in the revised manuscript.
RESPONSE:
We have now recalculated the costs (now converted to 2018 Euros) and added confidence intervals to the last columns in the tables and in the text. In the main analysis we calculated the confidence intervals based on a t-test, whereas the confidence intervals in the subanalysis where the costs were weighted by time-at-risk were calculated by bootstrapping.
RESPONSE: The reviewer's point is well taken. We have now added to the discussion in the revised manuscript. Overall, we believe that the complex clinical status of patients with CKD, HF or diabetes and concomitant HK translates to an economic impact on healthcare systems and providers that is equally complex to disentangle and assign to specific causalities. Our study attempts for the first time in a non-US, nationally funded healthcare system, to assess the HRU burden associated with HK and quantify it in monetary terms. We cannot prove from our observational study design whether HK is the direct cause of hospital admissions and increased HRU, and we have emphasized this in several places in the manuscript. With our method, we are trying to assess as closely as possible the economic burden associated with HK in key comorbid patient cohorts, without implying that costs will solely be driven by HK, we are certain they will be partly driven by other events. The "difference-in-difference" method aims to address and control for this. Nevertheless, in order to understand the potential impact of new emerging drug therapies for HK, we think it is important to assess the costs in patients with HK events occurring in real-life, even if HK-related costs are unlikely to be causally driven by HK alone. Implications of the high costs observed arethat -if HK is at least partly contributing to the adverse health outcomes observed -successful efforts to reduce the burden of HK in key comorbid patient groups may have important economic impact. RESPONSE: Please see our answer above. In the revised manuscript, we have assessed primary (first-listed) diagnosis chapters from those patients who were hospitalized, please see Supplementary Table S4 . We observed that frequent diagnoses were those often seen in elderly highly comorbid patients, such as fractures, infection, dehydration, cardiac disease, etc. HK elevation per se is unlikely to be often coded as a primary diagnosis, even if it was a contributory cause, see above.
The 'Conclusions' in the abstract should provide some indication of the value of this research.
Currently it restates some of the results. RESPONSE: We have added a section on this.
The main cost results are excess costs over 6 months. This needs to be made clearer throughout the manuscript whenever results are presented. RESPONSE: We agree and have aimed to clarify our analytic approach, please see also responses to reviewer #2. Our main cost results indeed are excess costs, stemming from a before-after analysis among people who all had experienced HK. From these "after vs. before HK (=excess) costs", we then subtract the cost difference related to natural disease course over time. This was estimated as the excess cost (after vs. before a matched index date) for comparison persons with the same disease but who did not experience HK before the index date. Thus, the comparison group only acts as a point of reference for natural disease course cost differences. Of note, we did not undertake a matched cohort outcome analysis that directly compared HK and non-HK individuals, as to simulate the design of a randomized clinical trial. It is clear from our Supplementary Tables S1 to S3 that even after matching on a wide range of factors, individuals with and without HK were still not fully comparable even before the index date of HK. Patients who later experience HK tend to be more frail and comorbid than others, which is difficult to fully control for. However, the strength of the selfcontrolled before-after analysis is that it takes underlying general frailty factors into account, by comparing individuals with themselves over a rather short period of time, i.e. before and after an acute event happens.
From Table 2 , there is some evidence of residual confounding after matching -i.e. some differences in characteristic profiles. What impact do the authors think this has on the results? RESPONSE: Please see our answer above regarding our main, self-controlled, before-after design. While matching was as close as possible, it was not perfect. We do not believe this imperfect matching has a major impact, because per design, we primarily compare HK patients with themselves, and we only use the comparisons to estimate the cost related to the natural disease course over time. In the revised manuscript, we have moved the entire characteristics of the comparisons to the appendix, to emphasize this.
RESPONSE: We agree. Rightly, we don't expect them to be similar, given the large differences between healthcare systems. We have reworded our sentence.
The Conclusions section of the paper is perhaps too strong given the limitations identified at the end of the Discussion. RESPONSE: We agree that some parts of the conclusions could be softened and have done so in the revised version.
Figure 4 presents costs and cost differences for each disease group. The bars showing the difference (when positive) should not be hovering up the scale. I realise they are showing the difference, but it may be misleading as they no longer conform to the y-axis values. They should start at 0 and end at the mean cost as standard. RESPONSE: We agree and have changed the figure as suggested.
Reviewer: 2
Reviewer Name: CS Sutherland Institution and Country: University of Basel, Switzerland Please state any competing interests or state 'None declared': I have worked with some of the industry competitors for some of the authors listed.
Please leave your comments for the authors below Overall it is nice to see an attempt to publish this data. There is limited information regarding hyperkalemic events in Europe, so the publication of this registry would be a welcomed additional to the available evidence. However there are some issues that need to be resolved prior to publication.
RESPONSE: We thank the reviewer for the kind remarks on our paper and for the good comments and suggestions which we feel have improved our manuscript. We have done our best to resolve any remaining issues. Please see our answers below. CRITICAL 1. Definition of case and controls It is not clear how the time-to-event of HK was treated. The authors state that registry provided data from 2005 to 2011 (approximately 7 years); but that the first HK was defined as not having an event in the previous month. Is this the previous month before entry into the cohort, or previous month at the time the data was analysed? Was the data censored? This needs to be clarified as HK is a recurring event and from the current description, cases and controls could be similar people just captured at different points in time. In fact, depending on how the data was handled, a case could be a less severe HK patient than a control, depending on when the HK occurred according to your current definition. Refer to figure below.
RESPONSE: We thank the reviewer for the possibility to clarify our methods better, and have aimed to do so in the updated manuscript. We aimed to study HRU and costs related to first incident HK events in people following incident exposure to a high-risk comorbidity (CKD, HF, or DM) . Thus by definition, people had to have a first record of the disease in question (e.g. CKD, HF, DM), before we start to follow them for subsequent incident HK. If a patient with incident diabetes had had a previous HK event e.g. 3 months before, or 3 years before, his or her first ever diabetes treatment record (i.e., the diabetes cohort entry), the patient would still be eligible to have a first incident HK event as a diabetes treated patient from the date of first diabetes cohort entry. If the patient had had a HK event recorded e.g. 1 week before first diabetes treatment, then a new HK measurement on the same date of diabetes treatment start, or up to 3 weeks after, was disregarded, because these measurements per definition were regarded part of the same (prevalent, not incident) HK event. HK and non-HK patients could thus not be e.g. "diabetic people with more or less repetitive hyperkalemia just captured at different points in time", as suggested, because only the first detected HK event while being a diabetes treated patient was regarded in the main cost analysis. Comparisons were therefore not allowed to have had any HK recorded at any time between the diabetes treatment start and the index date of the matched HK patient. Our definition also allowed us to identify second, third and fourth HK events for descriptive purposes.
Matching of case and controls
There has been an attempt to match the cases and controls, however there are no p values provided in Table 2 or the supplementary tables? This is essential to know if there are statistically significant differences at the baseline. For instance, the proportion of late stage renal disease is almost double in the patients with HK (i.e. GFR less than 15 cases = 11.1% in CKD vs eGFR less than 15 controls 5.2%)? This alone could account for the differences in the costs. Hence is the conclusion that HK costs are higher, or that patients with more severe renal disease have higher costs? One can appreciate that these are complicated patients, but there needs to be an adjustment or re-assessment of this to truly determine the costs associated with HK.
RESPONSE: Our main analysis is a before-after analysis among people who all had experienced HK. We have outlined this in the revised manuscript and created a new figure (Figure 1 ) to clarify this. We estimate the initial cost of hyperkalemia, i.e. the "after vs. before HK (=excess) costs" internally among the HK patients. The strength of the self-controlled before-after analysis is that it takes underlying general frailty factors into account, by comparing individuals with themselves over a rather short period of time, i.e. before and after an acute event happens. As we know the initial cost of hyperkalemia is affected by the cost related to the natural disease course over time, we estimated this cost as the difference "after vs. before a matched index date" among the comparisons with the same underlying comorbidity but who did not experience HK. Thus, the comparison cohort just acted as an external point of reference for "natural disease course cost differences over time", not as direct comparisons after the index date. We thus did not undertake a matched cohort outcome analysis that directly compared HK and non-HK individuals, as in a simulation of a randomized clinical trial. It is therefore of minor importance that, as the reviewer correctly refers to, even after matching on a wide range of factors, HK and non-HK individuals were not fully comparable at baseline, i.e. already before the index date of HK. Thus, the conclusion is that e.g. the HRU and costs in a group of CKD patients with moderate to severe renal disease increase substantially after a first incident HK event, compared with the time shortly before the HK event.
Among similarly old and comorbid CKD patients (although with slightly better average eGFR) who do not experience HK, HRU and costs increase much more slowly and gradually over time.
Differentiation of comorbidities
The authors have divided the cohort into 3 groups, CKD, CHF and diabetes; however still is substantial overlap in these patient populations and these patients are clinically different. There should actually be several categories (i.e. CKD only, CHF only, diabetes (defined % type I or II), CKD+CHF+diabetes, CKD +CHF, CKD+diabetes, diabetes+CHF, etc.), or the comordities need to be adjusted for in the analysis. This is especially important since again there is an imbalance in your case-controls. RESPONSE: Please see our answer above. Our main analysis is a before-after analysis, in which comorbidities are inherently adjusted for, to compare costs before and after HK event. Secondly, the main rationale of our study was that our disease populations reflect the true real-world populations with e.g. diabetes, at the time of first diabetes treatment, rather than restricted populations where certain comorbidities are excluded. The three patient populations should therefore be seen as 3 different independent populations, not as 1 including patients at different time points. Diabetes patients in real-life often have CKD, HF, and other comorbidities, these overlaps are part of the clinical reality of individuals at high risk of HK, and of patients who develop HK. 
